drugset / Trial / NCT00457392

A Study In Patients With Non-Small Cell Lung Cancer To Test If Erlotinib Plus SU011248 Is Better Than Erlotinib Alone

NCT00457392

Phase 3 Completed 960 enrolled Pfizer
RandomizedParallel-groupTriple-blindTreatment

Summary

This study will test whether treatment with erlotinib plus SU011248 is better than erlotinib alone in patients with advanced/metastatic lung cancer who have received previous treatment with a platinum-based regimen.

Timeline

Start
2007-07
Primary completion
2010-07
Completion
2012-12

Drugs

EvaluationDrugModalityDoseRoute
Subject Sunitinib Small molecule 37.5 mg Oral
Comparator Erlotinib Small molecule 150 mg